Items Tagged ‘cedirnaib’

October 21st, 2014

Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival but Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer


The addition of the antiangiogenic agent cediranib to the PARP inhibitor olaparib in women with recurrent platinum-sensitive ovarian cancer improves time to cancer progression and survival. The results of this study were recently reported in The Lancet Oncology. Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than […]

View full entry

Tags: cedirnaib, News, olaparib, Ovarian Cancer, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer